TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
Metabolic syndrome in women with polycystic ovary syndrome
Key Statistics
- 33% — Prevalence of metabolic syndrome in PCOS
- 10–18% — PCOS prevalence, reproductive age
- 5–10% — Target weight loss, year 1
Don't-miss facts
-
Metabolic syndrome affects 33% of PCOS; JIS (2009) criteria = ≥3 of 5 (waist circumference, triglycerides, HDL-C, BP, fasting glucose)
-
PCOS doubles CHD/stroke risk (55% increase after BMI adjustment); metabolic syndrome → 5-fold diabetes type II risk
-
PCOS → up to 30-fold ↑OSA risk and depression OR 4.03 (independent of BMI) – screen and refer
-
Endometrial cancer risk: PCOS OR 2.89; metabolic syndrome OR 1.6
-
Lifestyle modification (5–10% weight loss year 1; 150 min/week exercise, 90 min moderate aerobic) is the only universally recommended intervention
-
Metformin (500–1500 mg/day) only evidence-supported in IGT to prevent diabetes progression, not for IR alone in normoglycaemic women
-
Statins reserved for dyslipidaemia only – teratogenic risk in reproductive-age women
-
Bariatric surgery threshold: BMI ≥40, or BMI 35–39.9 with comorbidity (diabetes/hypertension); reduced PCOS incidence from 45.6% to 6.8% at 12 months in one meta-analysis
Diagnostic definitions at a glance
Central obesity-based: NCEP:ATP III, AHA/NHLBI, IDF, JIS Insulin resistance-based (historic): WHO, EGIR, AACE
Abbreviation Key
- PCOS — polycystic ovary syndrome
- AACE — American Association of Clinical Endocrinology
- IR — insulin resistance NCEP:ATP
- III — National Cholesterol Education Program Adult Treatment Panel III
- CVD — cardiovascular disease
- AHA/NHLBI — American Heart Association/National Heart, Lung,
- CHD — coronary heart disease and Blood Institute
- BMI — body mass index
- IDF — International Diabetes Federation
- OSA — obstructive sleep apnoea
- JIS — Joint Interim Statement
- IGT — impaired glucose tolerance
- MI — myoinositol
- OR — odds ratio
- DCI — d-chiro-inositol
- WHO — World Health Organization
- GLP-1R — glucagon-like peptide-1 receptor
- EGIR — European Group for the study of Insulin Resistance
Source: Metabolic syndrome in women with polycystic ovary syndrome. The Obstetrician & Gynaecologist 2018;20:245–252. doi:10.1111/tog.12519
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).